Skip to content

Advertisement

  • Short report
  • Open Access

Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort

Contributed equally
Translational Neurodegeneration20187:31

https://doi.org/10.1186/s40035-018-0136-6

  • Received: 5 July 2018
  • Accepted: 23 October 2018
  • Published:

Abstract

Background

The TANK-Binding Kinase 1 (TBK1) gene has recently been identified as the third or fourth most frequent cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The aim of this study was to assess the genetic contribution of TBK1 in a Chinese cohort.

Methods

A total of 270 cases with ALS, FTD, or their combination were recruited into this study. All the coding exons of TBK1 and intron-exon boundaries were sequenced using Sanger sequencing. The frequency of TBK1 variants and the correlation with clinical phenotypes were analyzed.

Results

A novel mutation (c.1959_1960insGT, p.E653fs) was identified in a sporadic case with semantic dementia, secondarily developing ALS. Another novel variant (c.2063_2064delTT, p.L688Rfs*14) was found in an ALS-FTD family. Totally, the TBK1 variants could only account for 0.7% of cases.

Conclusions

This study enlarges the genetic and phenotypic spectrum of TBK1 mutation in a Chinese cohort. Our data indicates that TBK1 mutation is not a common cause for ALS and FTD in Chinese patients.

Keywords

  • Amyotrophic lateral sclerosis
  • Frontotemporal dementia
  • TBK1 gene

Background

Amyotrophic lateral sclerosis (ALS) is a multisystem degenerative condition clinically characterized by the predominant loss of motor neurons and progressive weakness of voluntarily innervated muscles, including muscles of the respiratory apparatus. Patients eventually die of respiratory failure within 3–5 years [1]. Frontotemporal dementia (FTD) is a focal clinical syndrome characterized by behavior changes and language impairment, associated with circumscribed degeneration of the prefrontal and anterior temporal cortex. Onset is typically in the middle years of life and survival is approximately 8 years [2]. Traditionally, ALS and FTD have been considered as two different neurodegenerative diseases; however, recent studies have indicated that both shared common clinical features, pathologic spectrum, and causative genes [3, 4]. Approximately 10% of patients with FTD presented clinical evidence of ALS at some stage in the disease course; conversely, above 10% to 15% of patients with ALS showed behavioral changes and/or language dysfunctions that met the diagnosis of FTD [5, 6]. Additionally, accumulation of TAR DNA-binding protein 43 (TDP-43) positive inclusions in the brain regions and motor neurons have been detected in both patients with FTD and ALS, which were considered as common neuropathology of both disorders [7]. In addition, the identification of TARDBP as the first shared ALS/FTD gene was followed by a wave of discovered causative genes, such as chromosome 9 open reading frame 72 (C9orf72), valosin-containing protein (VCP), which could cause both ALS and FTD [810]. In summary, ALS and FTD have been increasingly regarded as part of a disease spectrum.

Recently, the TANK-binding kinase 1 (TBK1) gene was identified to be highly associated with ALS and FTD [11]. So far, at least 100 variants in the TBK1 gene, including loss of function variants, in-frame deletions of single amino acids, and missense variants, have been reported in ALS, FTD, or ALS-FTD patients, thus making TBK1 the third or fourth most frequent genetic cause of ALS and FTD [12]. TBK1 protein is a multifunctional kinase, which is known to bind to and phosphorylate a series of proteins involved in innate immunity and autophagy, including optineurin (OPTN) and p62, both of which have been implicated in the process of ALS [13, 14].

In this study, we screened a cohort of 270 cases with ALS, FTD and ALS-FTD from the Chinese Han population, and then determined the TBK1 variant frequencies and the correlation with clinical phenotypes.

Methods

Subjects

A total of 270 cases were recruited into this study, including 180 cases with ALS (age of onset: 47.5 ± 13.0 years; male: 70.0%; family history: 9.4%), 88 cases with FTD (age of onset: 56.1 ± 10.1 years; male: 42.1%; family history: 12.5%), a sporadic case with FTD-ALS (age at onset: 61 years; female), and an ALS-FTD family (age at onset of proband: 45 years; male). Mutations in the most common causative ALS genes (SOD1, TARDBP, FUS, C9orf72) and FTD genes (MAPT, GRN, C9orf72) were excluded by Sanger sequencing or repeat-primed polymerase chain reaction (PCR, for C9orf72). All cases were enrolled from outpatients and inpatients of the department of Neurology, Xiangya Hospital, Central South University. All ALS cases met the EI Escorial criteria for clinical ALS diagnosis [15], and all FTD cases were diagnosed according to the consensus criteria for FTD [16]. The 300 healthy individuals (age mean: 68.8 ± 9.0 years; male: 63.3%) were collected from Xiangya Hospital Wellness Center, and their Mini-Mental State Examination (MMSE) scores were equal or above 28 points. The study was approved by the Ethics Committee of Xiangya Hospital of the Central South University in China (equivalent to an Institutional Review Board). Written informed consent was obtained from each participant.

Gene screening and genotyping

Genomic DNA was extracted from peripheral blood leukocytes using standard methods. The quality and quantity of DNA were assessed with a fluorometer. All DNA samples were normalized to 50 ng/ul. All subjects were screened for all exons of TBK1 (NM_013254) using Sanger sequencing. All primers designed by Primer 5 software, were applied to amplify coding regions and flanking non-coding regions of TBK1 using PCR. The primers and PCR reaction conditions are listed in Additional file 1: Table S1. PCR products were sequenced using identical forward and reverse primers with BigDye terminator v3.1 sequencing chemistry on an ABI 3730xl DNA analyzer (Applied Biosystems). The DNA sequences were then analyzed by Sequencher software, version 4.2.

Results

In this study, we respectively identified two novel mutations c.1959_1960insGT, p.E653fs and c.2063_2064delTT, p.L688Rfs*14 in a sporadic case with FTD-ALS and in an ALS-FTD family (Fig.1a and b). These two variants were not detected in 300 healthy controls, and were also absent in the following database: the HGMD database ( http://www.hgmd.cf.ac.uk/ac ), the Exome Aggregation Consortium ( http://exac.broadinstitute.org ), NHLBI Exome Sequencing Project (( http://evs.gs.washington.edu/EVS ), the dpSNP database ( http://www.ncbi.nlm.nih.gov/snp ), and the 1000 Genomes Project (result in different data set: Asian, 2012 Apr; CHB (Northern Chinese); JPT (Japanese); CHS (Southern Han Chinese). These two mutations were also predicted to have disease-causing effects using online prediction software (http://sift.jcvi.org/).
Fig. 1
Fig. 1

Sanger sequencing showed two nover TBK1 novel mutations. a mutation c.1959_1960insGT, p.E653fs in a sporadic case with FTD-ALS; b mutation c.2063_2064delTT, p.L688Rfs*14 in an ALS-FTD family

The p.E653fs mutation carrier was a 63-year-old female with a 2-year history of disease. At 61 years of age, the patient presented initial symptoms such as difficulties in finding words and reduced word comprehension. The patient’s husband could not understand her speech due to the use of meaningless words. She also could not say the names of items, such as “key”, “watch”, etc., which were familiar in her daily life. One year later, she experienced progressive weakness in the right limbs, and the symptoms of dysphagia and dysarthria occurred in the last 2 months. Neurologic examination revealed hyperreflexia in the right side; muscle testing showed a score of 4/5 points in proximity and extremity of right side muscles. Hoffmann and Babinski signs were both positive in the right side. The electromyogram (EMG) showed spontaneous denervation activity in the affected limbs. With regard to cognitive assessment, at the beginning, her Mini-Mental State Examination (MMSE) score was 21/30 points, and her Montreal Cognitive Assessment (MoCA) score was 11/30 points; however, 2 years later, she could not finish the above cognitive assessment. Magnetic resonance imaging (MRI) of the brain reported brain atrophy, especially in left temporal lobe (Fig. 2a). The fluorodeoxyglucose positron emission tomography (FDG-PET) indicated that glucose metabolism decreased in left temporal lobe and hippocampus (Fig. 2b). In summary, this patient was clinically diagnosed with semantic dementia (SD), a subtype of FTD, secondarily developing ALS. Unfortunately, it was not possible to verify segregation of the variant with the disease in the family, because the patient had no information about her birth family.
Fig. 2
Fig. 2

The brain neuroimaging of SD-ALS patient carrying p.E653fs mutation. a MRI showed left temporal lobe atrophy;b FDG-PET indicated that glucose metabolism decreased in the left temporal lobe and hippocampus

The L688Rfs*14 variant was identified in an ALS-FTD family (Fig. 3a). The proband was a 45-year-old male (II: 2), who initially presented left upper limb weakness and atrophy, which extended bilaterally to the neck, shoulder and right upper limb within 4 months. At the time of diagnosis, 6 months after the clinical onset, he had both upper and lower motor signs, slight dysarthria and dysphagia. The EMG showed extensive neurogenic damage, involving brainstem and cervicothoracic and lumbosacral segments. The general cognition assessment was normal (MMSE: 30, MoCA: 29). His father (I: 1) had similar symptoms to those of the proband, and died when he was 44 years old. His 50-year-old brother (II: 1), who also carried that L688Rfs*14 mutation, had been bright and sociable, however, at 36 years of age, he presented progressively bizarre behaviors including withdrawal from social engagements and dishevelment in public. Brain MRI indicated frontotemporal lobe and hippocampus atrophy (Fig. 3b). We also found that he had the mirror image dextrocardias with situs inversus viscera (Fig. 3c). Their mother (I: 2) without similar symptoms did not carry this mutation.
Fig. 3
Fig. 3

(a) The pedigree of the ALS-FTD family with L688Rfs*14 variant, the proband is indicated with an arrow; (b) brain MRI of the II:1 case reported frontotemporal lobe and hippocampus atrophy; (c) chest X-ray of the II:1 case reported that he had mirror image dextrocardias with situs inversus viscera

Discussion

In this study, we screened a Chinese cohort of 270 cases with ALS, FTD, FTD-ALS (or ALS-FTD) for TBK1 mutations and identified two novel frame-shift TBK1 mutations (p.E653fs and p.L688Rfs*14) in a sporadic case with SD-ALS and an ALS-FTD family respectively, accounting for 0.7% of total cases, which were consistent with the recent Asian population studies from Taiwan (0.5%; 1/207 ALS) and China (0.7%; 2/294 ALS) [17, 18], although they were significantly lower than European cohorts, such as Italian (3.2%; 5/154 ALS) and Belgian (1.7% 11/629 ALS, FTD, FTD-ALS) [19, 20]. Our results further indicated that the TBK1 gene was not a common gene in the Chinese population.

The TBK1 gene contains four domains, N-terminal kinase domain (KD), ubiquitin-like domain (ULD), a-helical scaffold dimerization domain (SDD), and C-terminal domain (CTD) [21]. The two mutations p.E653fs and p.L688Rfs*14 identified in this study were both located in the CTD region, which were critical in TBK1 protein function. A previous study confirmed that the OPTN binding region (amino acids: 601–729) was located in CTD, therefore, we speculate that these two variants have probably lost their ability to interact with OPTN, thus leading to ALS or FTD.

All TBK1 variants were summarized as three types: loss of function (LoF) variants, in-frame deletions of single amino acids, and missense variants. LoF variants resulting in a 50% reduction of TBK1, could explain 0.4–3.4% of ALS, 0.2–1.3% of FTD and 3.3–4.5% of FTD–ALS [22]. The LoF variants involved premature termination codons (PTCs), insertions, deletions, or splice site mutations resulting in a frame-shift or an in-frame deletion of multiple amino acids [12]. Therefore, the two mutations p.E653fs and p.L688Rfs*14 identified in this study both belong to LoF variants, further implicating their pathogenicity. Further studies should focus on whether these two mutations decrease the TBK1 mRNA and protein levels.

With regard to the TBK1 genotype-phenotype relationship, more than half of patients with LoF variants were clinically diagnosed with pure motor neuron disease (MND), which mainly comprised ALS, rare cases with progressive bulbar palsy. Approximately one quarter of TBK1 mutation carriers were diagnosed with pure FTD, a few with unspecified dementia and above one fifth with a combination of ALS and FTD or unspecified dementia [23]. Interestingly, the two mutations detected in this study were both from cases with FTD combined with ALS. Through reviewing previous studies, we found a total of 54 index patients and 33 affected relatives with an LoF mutation in TBK1 for whom clinical information was available. Among them, seven variants, including Val479GlufsX4, Ala417X, 690_713del, Arg440X, Arg444X, Thr79del, Thr462LysfsX3 and Glu643del, were identified in ALS-FTD or FTD-ALS cases [11, 12, 18, 23, 24]. Therefore, this study enlarged the TBK1 genotype. Interestingly, four patients with TBK1 FTD–ALS from French–Portuguese cohort predominantly had language symptoms [25], secondarily developing ALS, which was similar to the p.E653fs mutation carriers in this study, suggesting that we should screen the TBK1 gene in patients who were clinically diagnosed as SD-ALS.

Conclusions

In summary, we found two novel TBK1 LoF variants in a Chinese cohort, which enlarged the gene mutation and clinic phenotype spectrum. To the best of our knowledge, this is the first report of FTD combined with ALS carrying the TBK1 mutation in the Chinese population, indicating that we should not neglect screening for the TBK1 gene when encountering the FTD-ALS or ALS-FTD cases.

Notes

Abbreviations

ALS: 

Amyotrophic lateral sclerosis

C9orf72

chromosome 9 open reading frame 72

CTD: 

C-terminal domain

FTD: 

Frontotemporal dementia

FUS

fused in sarcoma

GRN

granulin precursor

KD: 

kinase domain

LOF: 

loss of function

MAPT

microtubule associated protein tau

MMSE: 

Mini-Mental State Examination

MND: 

motor neuron disease

MoCA: 

Montreal Cognitive Assessment

PCR: 

polymerase chain reaction

PTCs: 

premature termination codons

SDD: 

scaffold dimerization domain

SOD1

superoxide dismutase 1

TBK1

TANK-binding kinase 1

TDP-43: 

TAR DNA-binding protein 43

ULD: 

ubiquitin-like domain

VCP

valosin-containing protein

Declarations

Acknowledgements

The authors are grateful to all subjects for participation in our study.

Funding

This study was supported by the National Natural Science Foundation of China (No.81471295 and No.81671075 to Lu Shen, No.81701134 to Bin Jiao), the National Key Plan for Scientific Research and Development of China (No.2016YFC1306000 to Beisha Tang), the Xiangya Hospital Youth Scientific Research Fund (No.2016Q01 to Bin Jiao).

Availability of data and materials

The materials used in the current study are available from the corresponding author on reasonable request.

Authors’ contributions

JB and SL conceived the study. JB, SQY and YZH performed the experiments and data analyses. WJL, ZL, YXX, and TBS gave the suggestions for this study. JB wrote the manuscript. SL revised the manuscript. All authors approved the manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Xiangya Hospital of the Central South University in China (equivalent to an Institutional Review Board). Written informed consent was obtained from each participant.

Consent for publication

Not applicable.

Competing interests

The authors report no actual or potential conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neurology, Xiangya Hospital, Central South University, 87 Xiangya Rd, Changsha, 410008, China
(2)
National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
(3)
Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
(4)
Department of Geriatrics Neurology, Xiangya Hospital, Central South University, Changsha, China
(5)
Parkinson’s Disease Center of Beijing Institute for Brain Disorders, Beijing, China
(6)
Collaborative Innovation Center for Brain Science, Shanghai, China
(7)
Collaborative Innovation Center for Genetics and Development, Shanghai, China
(8)
Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China

References

  1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942–55.View ArticleGoogle Scholar
  2. Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4(11):771–80.View ArticleGoogle Scholar
  3. Burrell JR, Halliday GM, Kril JJ, Ittner LM, Gotz J, Kiernan MC, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388(10047):919–31.View ArticleGoogle Scholar
  4. Weishaupt JH, Hyman T, Dikic I. Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia. Trends Mol Med. 2016;22(9):769–83.View ArticleGoogle Scholar
  5. Hsieh S, Caga J, Leslie FV, Shibata M, Daveson N, Foxe D, et al. Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression. J Geriatr Psychiatry Neurol. 2016;29(1):3–10.View ArticleGoogle Scholar
  6. Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10(2):162–72.View ArticleGoogle Scholar
  7. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3.View ArticleGoogle Scholar
  8. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40(5):572–4.View ArticleGoogle Scholar
  9. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–56.View ArticleGoogle Scholar
  10. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857–64.View ArticleGoogle Scholar
  11. Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631–6.View ArticleGoogle Scholar
  12. Freischmidt A, Muller K, Ludolph AC, Weishaupt JH, Andersen PM. Association of Mutations in TBK1 with sporadic and familial amyotrophic lateral sclerosis and frontotemporal dementia. JAMA Neurol. 2017;74(1):110–3.View ArticleGoogle Scholar
  13. Li F, Xu D, Wang Y, Zhou Z, Liu J, Hu S, et al. Structural insights into the ubiquitin recognition by OPTN (optineurin) and its regulation by TBK1-mediated phosphorylation. Autophagy. 2018;14(1):66–79.View ArticleGoogle Scholar
  14. Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015;130(1):77–92.View ArticleGoogle Scholar
  15. Brooks BR, El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci. 1994;124(Suppl):96–107.View ArticleGoogle Scholar
  16. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57(4):416–8.View ArticleGoogle Scholar
  17. Shu S, Li XL, Liu Q, Liu F, Cui B, Liu MS, et al. Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7–8):605–7.View ArticleGoogle Scholar
  18. Tsai PC, Liu YC, Lin KP, Liu YT, Liao YC, Hsiao CT, et al. Mutational analysis of TBK1 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2016;40:191.e11–6.View ArticleGoogle Scholar
  19. Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B, et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015;85(24):2116–25.View ArticleGoogle Scholar
  20. Pozzi L, Valenza F, Mosca L, Dal Mas A, Domi T, Romano A, et al. TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. J Neurol Neurosurg Psychiatry. 2017;88(10):869–75.View ArticleGoogle Scholar
  21. Gleason CE, Ordureau A, Gourlay R, Arthur JS, Cohen P. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon beta. J Biol Chem. 2011;286(41):35663–74.View ArticleGoogle Scholar
  22. Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C. Genotype-phenotype links in frontotemporal lobar degeneration. Nat Rev Neurol. 2018;14(6):363–78.View ArticleGoogle Scholar
  23. van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B, et al. TBK1 mutation Spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum Mutat. 2017;38(3):297–309.View ArticleGoogle Scholar
  24. Van Mossevelde S, van der Zee J, Gijselinck I, Engelborghs S, Sieben A, Van Langenhove T, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain. 2016;139(Pt 2):452–67.View ArticleGoogle Scholar
  25. Caroppo P, Camuzat A, De Septenville A, Couratier P, Lacomblez L, Auriacombe S, et al. Semantic and nonfluent aphasic variants, secondarily associated with amyotrophic lateral sclerosis, are predominant frontotemporal lobar degeneration phenotypes in TBK1 carriers. Alzheimers Dement (Amst). 2015;1(4):481–6.Google Scholar

Copyright

© The Author(s). 2018

Advertisement